Senate Democrats Push Full Cannabis Legalization as Trump Backs Rescheduling

Senate Democrats have introduced comprehensive federal cannabis legalization legislation, creating a stark policy divide as the Trump administration pursues the more limited approach of rescheduling marijuana from Schedule I to Schedule III. The Cannabis Administration and Opportunity Act represents the most ambitious federal reform proposal, seeking to remove cannabis entirely from the Controlled Substances Act rather than simply moving it to a lower drug schedule.

The competing approaches highlight the regulatory uncertainty that continues to weigh on cannabis sector valuations. Full legalization would eliminate the 280E tax burden that prevents cannabis companies from deducting standard business expenses, potentially boosting profit margins across the industry by 15-25%. Rescheduling to Schedule III would provide partial 280E relief but maintain federal restrictions on interstate commerce and banking access.

Multi-state operators like Curaleaf (CURLF), Green Thumb Industries (GTBIF), and Trulieve (TCNNF) face particular strategic challenges under this policy uncertainty. These companies have built state-by-state operations anticipating eventual federal reform, but the timeline and scope of that reform directly impacts their expansion strategies and capital allocation decisions. Full legalization would enable true interstate commerce, potentially disrupting current market dynamics where companies maintain separate cultivation and processing facilities in each state.

The legislative reality suggests neither proposal advances quickly through a divided Congress. Republicans generally favor more incremental approaches, while progressive Democrats push for comprehensive reform that includes social equity provisions and expungement programs. This political stalemate extends the current patchwork of state-legal markets operating under federal prohibition, maintaining the regulatory premium that keeps cannabis stocks trading at discounts to traditional consumer goods companies.

Investors should expect continued volatility around federal policy developments, as cannabis stocks remain highly sensitive to regulatory headlines. The sector's institutional investment limitations persist until federal banking and listing restrictions lift, constraining capital access and maintaining elevated borrowing costs across the industry. While both rescheduling and legalization represent positive developments, the divergent approaches underscore the complex path toward federal cannabis reform.